Tivantinib

From WikiMD.org
Jump to navigation Jump to search

Tivantinib

Tivantinib (pronounced ti-van-ti-nib) is an experimental cancer drug that is being studied for its potential use in the treatment of various types of cancer, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

Etymology

The name "Tivantinib" is derived from the combination of the prefix "Tivan-", which is a proprietary designation, and the suffix "-tinib", which is commonly used in the names of tyrosine kinase inhibitors (TKIs). The "-tinib" suffix indicates that the drug works by inhibiting the activity of one or more tyrosine kinases, enzymes that play a key role in the signaling pathways that regulate cellular processes such as growth, division, and death.

Mechanism of Action

Tivantinib is a non-ATP competitive inhibitor of the c-Met receptor tyrosine kinase. By inhibiting c-Met, Tivantinib disrupts the signaling pathways that promote cancer cell growth and survival, thereby potentially slowing or stopping the progression of the disease.

Clinical Trials

Tivantinib has been evaluated in several clinical trials, including a Phase III trial for HCC, a Phase II trial for NSCLC, and a Phase I trial for CRC. The results of these trials have shown promise, but further research is needed to fully understand the drug's efficacy and safety profile.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski